Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC40A1 | Q9NP59 | 17/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | NFKBIA | P25963 | 4/20 | 1.00 |
| ▸ | RELA | Q04206 | 3/20 | 1.00 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.66 |
| ▸ | G6PD | P11413 | 1/20 | 0.66 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.66 |
| ▸ | METAP2 | P50579 | 1/20 | 0.66 |
| ▸ | METAP1 | P53582 | 1/20 | 0.66 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.66 |
| ▸ | ATM | Q13315 | 1/20 | 0.66 |
| ▸ | MDM4 | O15151 | 1/20 | 0.65 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.65 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31676665 | 1.00 | SLC40A1 (1.00) | SLC40A1TDP1MEN1KMT2ANFKBIA | |
| Formic Acid Methyl Ester SCHEMBL28105309 | 0.91 | SLC40A1 (0.82) | SLC40A1TDP1MEN1KMT2ANFKBIA | |
| SCHEMBL7896798 | 0.89 | SLC40A1 (0.80) | SLC40A1TDP1MEN1KMT2ANFKBIA | |
| SCHEMBL27214248 | 0.87 | SLC40A1 (0.78) | SLC40A1TDP1MEN1KMT2ANFKBIA | |
| SCHEMBL30925552 | 0.87 | SLC40A1 (0.78) | SLC40A1TDP1MEN1KMT2ANFKBIA | |
| SCHEMBL30854809 | 0.87 | SLC40A1 (0.76) | SLC40A1TDP1MEN1KMT2ANFKBIA | |
| SCHEMBL1507919 | 0.87 | SLC40A1 (0.76) | SLC40A1TDP1MEN1KMT2ANFKBIA | |
| SCHEMBL6981201 | 0.84 | SLC40A1 (0.73) | SLC40A1TDP1MEN1KMT2ANFKBIA | |
| SCHEMBL11973157 | 0.84 | SLC40A1 (0.73) | SLC40A1TDP1MEN1KMT2ANFKBIA | |
| SCHEMBL11973660 | 0.84 | SLC40A1 (0.73) | SLC40A1TDP1MEN1KMT2ANFKBIA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230201437-A1 | GAS TREATMENT DELIVERY SYSTEMS AND METHODS | Immunores-Therapeutics, LLC | 2023-06-29 | — | — | US | disclosed |
| US-11471579-B2 | Gas treatment delivery systems and methods | Immunores-Therapeutics, LLC (US) | 2022-10-18 | — | — | US | disclosed |
| US-11413278-B2 | Compounds and methods for promoting stress resistance | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-16 | — | — | US | disclosed |
| US-20190351125-A1 | GAS TREATMENT DELIVERY SYSTEMS AND METHODS | Immunores-Therapeutics, LLC | 2019-11-21 | — | — | US | disclosed |
| EP-3500277-A1 | GAS TREATMENT DELIVERY SYSTEMS AND METHODS | Immunores-Therapeutics, LLC (US) | 2019-06-26 | — | — | EP | disclosed |
| WO-2018035504-A1 | GAS TREATMENT DELIVERY SYSTEMS AND METHODS | LANE RONALD HOWARD (US) | 2018-02-22 | — | — | WO | disclosed |
| EP-2675526-B1 | NOVEL SULFONAMINOQUINOLINE HEPCIDIN ANTAGONISTS | VIFOR (INTERNATIONAL) AG (CH) | 2017-02-01 | — | — | EP | disclosed |
| US-20160310528-A1 | Castration-Resistant Prostate Cancer | NUTECH VENTURES | 2016-10-27 | — | — | US | disclosed |
| US-20160310528-A1 | Castration-Resistant Prostate Cancer | NUTECH VENTURES | 2016-10-27 | — | — | US | disclosed |
| US-9102688-B2 | Sulfonaminoquinoline hepcidin antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2015-08-11 | — | — | US | disclosed |
| US-20140364424-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2014-12-11 | — | — | US | disclosed |
| US-20140364424-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2014-12-11 | — | — | US | disclosed |
| US-20140275165-A1 | COMPOUNDS THAT INHIBIT NFkB AND BACE1 ACTIVITY | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2014-09-18 | — | — | US | disclosed |
| EP-2675526-A1 | NOVEL SULFONAMINOQUINOLINE HEPCIDIN ANTAGONISTS | Vifor (International) AG (CH) | 2013-12-25 | — | — | EP | disclosed |
| WO-2012110603-A1 | NOVEL SULFONAMINOQUINOLINE HEPCIDIN ANTAGONISTS | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-23 | — | — | WO | disclosed |
| US-20120214803-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-23 | — | — | US | disclosed |
| US-20120214803-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-23 | — | — | US | disclosed |
| US-20120214803-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-23 | — | — | US | disclosed |
| US-20120064099-A1 | COMPOUNDS THAT INHIBIT NFKB AND BACE1 ACTIVITY | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2012-03-15 | — | — | US | disclosed |
| WO-2010051064-A1 | COMPOUNDS THAT INHIBIT NFκB ACTIVITY | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214803-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | HAMP, SLC40A1, FTH1 | SLC40A1 2/4885TDP1 4862/4885MEN1 2680/4885 |
| US-20160310528-A1 | Castration-Resistant Prostate Cancer | UGDH, G6PD, DPYD | SLC40A1 3904/4885TDP1 1220/4885MEN1 2328/4885 |
| US-20140275165-A1 | COMPOUNDS THAT INHIBIT NFkB AND BACE1 ACTIVITY | NFKBIA, BACE1, BACE2 | SLC40A1 3410/4885TDP1 567/4885MEN1 4238/4885 |
| US-20120064099-A1 | COMPOUNDS THAT INHIBIT NFKB AND BACE1 ACTIVITY | NFKBIA, BACE1, BACE2 | SLC40A1 3410/4885TDP1 567/4885MEN1 4238/4885 |
| US-20140364424-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | HAMP, SLC40A1, FTH1 | SLC40A1 2/4885TDP1 4862/4885MEN1 2680/4885 |
| US-11413278-B2 | Compounds and methods for promoting stress resistance | HSPA9, ATF4, GPX4 | SLC40A1 1579/4885TDP1 2088/4885MEN1 4867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.